2. van Dieren JM, van der Woude CJ, Kuipers EJ, et al. Roles of CD1d-restricted NKT cells in the intestine. Inflamm Bowel Dis 2007;13:1146-1152.
5. Tefit JN, Davies G, Serra V. NKT cell responses to glycolipid activation. Methods Mol Biol 2010;626:149-167.
6. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 2004;82:315-322.
7. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med 2009;9:4-14.
9. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.
10. Saubermann LJ, Beck P, De Jong YP, et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000;119:119-128.
18. Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol 2011;140:142-151.
21. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-3709.
22. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005;11:1910-1917.
24. Schneiders FL, Scheper RJ, von Blomberg BM, et al. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011;140:130-141.